What's new?
04/04/2018

• Sofinnova Crossover 1 est le plus grand fonds crossover dédié à la santé en Europe.
• Avec ce nouveau fonds, Sofinnova Partners poursuit activement sa stratégie visant à élargir sa plateforme d’investissements en sciences de la vie sur l’ensemble de la chaîne de valeur, de l’amorçage aux sociétés de croissance.
• Bpifrance* et CNP Assurances sont co-sponsors du fonds.

Paris, France – 4 avril 2018 — Sofinnova Partners, un leader du capital-risque en Europe spécialisé dans les sciences de la vie, annonce le lancement de son premier fonds crossover dédié à la santé en Europe, d’un montant de 275 millions d’euros (340 millions de dollars), au-delà de l’objectif du premier closing à 250 millions d’euros. Avec ce nouveau fonds, Sofinnova Partners franchit une étape supplémentaire dans le déploiement de son projet de croissance visant à étendre son champ d’intervention dans les différents segments de l’investissement dans les sciences de la vie, grâce à des équipes dédiées.

Dans la continuité de la stratégie appliquée avec succès depuis plusieurs décennies avec ses fonds Capital intervenant en early-stage, Sofinnova Crossover I investira dans la biopharmacie et l’instrumentation médicale. Il ciblera en priorité des technologies de rupture permettant des innovations thérapeutiques portées par des équipes managériales expérimentées. Sofinnova Partners investira comme chef de fil ou investisseur de référence dans une quinzaine d’entreprises privées ou cotées. Environ 80% du fonds seront investis en Europe, et les 20% restants ailleurs, principalement en Amérique du Nord. Une équipe de quatre associés très expérimentés investira le fonds, en s’appuyant sur l’expérience élargie de Sofinnova Partners, son track record et son organisation. Ce nouveau fonds a su attirer la confiance d’investisseurs internationaux de premier plan, notamment des fonds souverains, compagnies d’assurance, corporate, et family offices. La majorité des fonds levés viennent d’Europe, en particulier de France, d’Italie, du Danemark, d’Irlande et de Suisse, mais aussi d’Asie avec des investisseurs originaires de Chine et de Singapour. En plus de BPIfrance* et de CNP Assurances, une société pharmaceutique chinoise de premier plan, le fonds public d’investissement danois, et des family offices tels que Fidim et KCK représentant de grandes familles industrielles d’Europe et d’Asie figurent parmi les investisseurs du nouveau fonds.

Antoine Papiernik, Président de Sofinnova Partners, déclare : “Avec le lancement de l’activité crossover, Sofinnova Partners construit sur son track record unique en early-stage. Beaucoup des entreprises que nous avons financées dès leur démarrage sont devenues au cours des années de grandes entreprises, certaines valorisées plusieurs milliards d’euros ; nous avons ainsi acquis une expérience unique sur la façon de les accompagner au stade d’après. Ce fonds complète notre plateforme d’investissement dans les sciences de la vie, nous permettant d’être actifs tout au long de la chaîne de valeur depuis l’investissement d’amorçage jusqu’aux phases plus avancées.”

Jacques Theurillat, Partner dans l’équipe crossover de Sofinnova Partners, poursuit : “Le marché européen de la santé est devenu mature avec des centaines d’entreprises privées et cotées à la recherche de fonds pour financer leur croissance, et Sofinnova Partners, avec son image de marque, son track record, et son expérience, est idéalement positionnée pour identifier les meilleures opportunités en Europe et accompagner leur transformation en leaders internationaux.”

Sur ce fonds Sofinnova Crossover I, Triago a agi en tant qu’agent de placement et Clifford Chance Europe LLP en tant que conseil juridique.

*Bpifrance intervient pour son compte propre et pour le compte du SGPI dans le cadre du Programme d’investissements d’Avenir (PIA)

Contact presse pour SOFINNOVA PARTNERS
Anne REIN Tel: +33 (0)6 03 35 92 05 @: anne.rein@strategiesimage.com

A propos de Sofinnova Partners
Sofinnova Partners est un des leaders du capital risque en Europe spécialisé dans les sciences de la vie. Basée à Paris, l’équipe est composée de professionnels issus d’Europe, des Etats Unis et de Chine. La société investit dans les technologies de changement de paradigme aux côtés d’entrepreneurs visionnaires. Sofinnova Partners intervient en priorité dans les start up et spin-off d’entreprises en tant qu’investisseur fondateur et chef de file. Depuis 45 ans, la société a accompagné plus de 500 entreprises à travers le monde devenues des leaders sur leur marché. Sofinnova Partners gère aujourd’hui 1,9 milliard d’euros.

25/11/2013

Pixium développe un système d’implants rétiniens pour restaurer la vision de patients aveugles.
Bpifrance, via le fonds InnoBio, participe au financement

Paris, France, 25 novembre 2013 – Pixium Vision (“Pixium”), qui développe des implants rétiniens électroniques pour des personnes ayant perdu la vue, a levé 15 M€ lors de l’extension d’un tour de table série A. Le financement a été mené par Sofinnova Partners, qui devient le premier actionnaire, avec le soutien actif de Bpifrance, via le fonds InnoBio, aux côtés des investisseurs existants de la série A Omnes Capital et Abingworth LLP. A cette occasion, Antoine Papiernik, de Sofinnova Partners, et Chahra Louafi, de Bpifrance, rejoignent le Conseil d’administration de la société.

Pixium a été co-cofondé par Bernard Gilly et José-Alain Sahel en novembre 2011 en étroite coopération avec l’Institut de la Vision, au sein du Centre Hospitalier National d’Ophtalmologie. Avec Pixium, le Dr. Gilly et le Pr. Sahel s’associent de nouveau à Sofinnova Partners après le succès de Fovea Pharmaceuticals, une société spécialisée dans les maladies oculaires qu’ils ont créée en 2005 et revendue avec succès à Sanofi en 2009.

Les fonds levés vont permettre de poursuivre le développement de IRIS, un dispositif d’implants rétiniens intelligents qui vise à permettre de recouvrer une vision proche de la normale pour les personnes ayant perdu la vue suite à des troubles dégénératifs de l’œil comme la rétinopathie pigmentaire, les autres dystrophies rétiniennes ou la dégénérescence maculaire liée à l’âge (DMLA). Pixium s’appuie sur les dernières découvertes et les avancées scientifiques dans les domaines du traitement neuronal, de la micro-électronique et de l’informatique. Les systèmes IRIS comprennent un implant intraoculaire placé dans l’œil du patient. Le patient porte une paire de lunettes dotée d’une mini-caméra intégrée et d’un émetteur sans fil. Les lunettes sont connectées à un ordinateur de poche, de la taille d’un smartphone, qui traite les images prises par la caméra en les convertissant en un signal que les lunettes transfèrent à l’implant rétinien pour stimuler les cellules ganglionnaires, qui envoient un signal au cerveau via le nerf optique afin de produire une image. Le patient suit un programme de rééducation qui apprend à son cerveau à interpréter les signaux émis par l’implant. Le système le plus avancé, IRIS1, est entré en essai clinique en avril 2013. Les résultats sur les premiers patients implantés sont attendus courant 2014 et seront à la base d’une demande de marquage CE.

Dr Gilly, Fondateur et CEO de Pixium, déclare : “Le soutien de nos investisseurs nous donne les moyens de finaliser les essais cliniques d’IRIS1, et d’envisager une autorisation réglementaire dans les deux prochaines années. Les fonds levés seront aussi utilisés pour développer les prochaines générations du système IRIS, dont le potentiel d’amélioration de la vision est encore plus grand, pouvant permettre aux patients d’accéder à une autonomie de vie bien supérieure au quotidien”.

Antoine Papiernik, Partenaire associé chez Sofinnova Partners, ajoute : “Au fil des ans, nous avons tissé des liens solides avec Bernard Gilly et José-Alain Sahel. Après Fovea Pharmaceuticals, que Sofinnova Partners a soutenu dès sa création, nous sommes ravis de rejoindre Pixium et de continuer à soutenir une équipe d’une telle qualité. La technologie de Pixium a le potentiel d’avoir un impact profond sur la vie des patients aveugles souffrants de rétinopathie pigmentaire ou de DMLA. C’est un privilège d’être associé à une entreprise développant un tel projet de rupture ».

Chahra Louafi, Directrice d’investissement chez Bpifrance, déclare : “Nous sommes ravis de pouvoir contribuer au développement de Pixium ; la technologie IRIS est extrêmement innovante et devrait représenter un progrès important pour les patients souffrants de cécité”.

Pour en savoir plus, consultez www.pixium-vision.com

Contacts pour Pixium Vision
Bernard Gilly, Chairman and CEO
bgilly@pixium-vision.com
+33 1 76 21 47 30

Citigate Dewe Rogerson 
Mark Swallow (London) / Lucie Larguier (Paris)
mark.swallow@citigatedr.co.uk / lucie.larguier@citigate.fr
+44 20 7282 2948 / +33 1 53 32 84 75

Contacts pour Sofinnova Partners
STRATEGIES & IMAGE 
Anne Rein 
anne.rein@strategiesimage.com
+33 (0)6 03 35 92 05

A propos de Pixium Vision
Pixium Vision développe des implants rétiniens électroniques innovants pour les personnes ayant perdu la vue. L’objectif est de restaurer la vision de ces patients et de leur permettre ainsi d’être plus autonomes. Pixium Vision s’appuie sur les toutes dernières découvertes scientifiques dans les domaines du traitement neuronal, de la micro-électronique et de l’informatique pour développer des systèmes d’implants rétiniens qui pourraient permettre aux personnes aveugles de retrouver une vision proche de la normale.

Le premier dispositif de Pixium Vision, IRIS1 (Intelligent Retinal Implant Systems), utilise un implant épi-rétinien et est actuellement en phase d’essais cliniques, qui seront à la base d’une demande de marquage CE. La société développe également un système de deuxième génération (IRIS2), construit sur le même modèle que le premier mais offrant une meilleure acuité visuelle. De plus, Pixium travaille actuellement sur IRIS3, un système d’implant sous-rétinien fondé sur des technologies encore plus innovantes.

Pixium Vision a été créé à Paris en novembre 2011 et est un spin-out de l’Institut de la Vision et de l’Université Pierre et Marie Curie à Paris. Le projet Pixium Vision repose sur le travail collaboratif de plusieurs équipes de recherche de haut niveau à travers l’Europe. Pixium Vision est soutenu par un syndicat d’investisseurs européens, incluant Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure et Polytechnos.

Pour en savoir plus, consultez www.pixium-vision.com

 

A propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris. Depuis plus de 40 ans, la société a financé près de 500 sociétés – start-up, spin-off et opérations de retournement. Elle a accompagné les plus grands entrepreneurs européens dans le domaine des sciences de la vie. Avec 1,3 milliard d’euros sous gestion, l’équipe de Sofinnova Partners, reconnue pour sa capacité à aider et à soutenir les entreprises de son portefeuille de la création à la sortie, a permis l’émergence de leaders sur leurs marchés. Pour en savoir plus, consultez sofinnova.social-unit.fr

A propos de Bpifrance et d’InnoBio
Les investissements en fonds propres de Bpifrance sont opérés parBpifrance Investissement. Bpifrance investit en minoritaire, directement via des fonds généralistes ou sectoriels, et indirectement via des fonds partenaires, dans les entreprises françaises, PME, ETI et grandes entreprises. InnoBio est un FCPR, de 139 millions d’euros, géré par Bpifrance qui en est également souscripteur (37 %) aux côtés des principaux laboratoires pharmaceutiques mondiaux (Sanofi Aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda, Boehringer-Ingelheim) opérant sur le territoire national. L’objectif principal du fonds est d’investir directement en fonds propres et quasi fonds propres au capital de sociétés fournissant des produits et services technologiques et innovants dans le domaine de la santé. InnoBio, composé d’une équipe d’investisseurs spécialistes du secteur, a réalisé son premier investissement janvier 2010. Pour en savoir plus, consultez www.bpifrance.fr

A propos d’Omnes Capital (anciennement Crédit Agricole Private Equity)
Omnes Capital est un acteur majeur du capital investissement, dédié au financement des PME. Avec 1,8 milliard d’euros d’actifs sous gestion et 160 sociétés accompagnées, Omnes Capital apporte aux entreprises les fonds propres nécessaires à leur développement à travers ses expertises de référence : Capital Développement & Transmission Small et Mid Cap, Capital Risque sur les segments des NTIC et des Sciences de la vie, Energies Renouvelables, Mezzanine,Fonds de fonds secondaire, Co-Investissement. Omnes Capital, anciennement Crédit Agricole Private Equity, était une filiale de Crédit Agricole S.A. jusqu’en mars 2012, date à laquelle la société a pris son indépendance. Omnes Capital est signataire des Principes pour l’Investissement Responsable des Nations Unies (PRI). Pour en savoir plus, consultez www.omnescapital.com

A propos de Abingworth
Abingworth est un groupe d’investissement international spécialisé dans les secteurs des sciences de la vie et de la santé. Le groupe investit en fonds propres dans des entreprises à tous les stades de leur développement, notamment en capital risque, en capital développement et dans des entreprises cotées.
Créé en 1973, Abingworth a accompagné de nombreuses entreprises reconnues sur leur marché. Les équipes d’Abingworth comptent 19 professionnels disposant d’expertises variées et d’un large réseau de contacts dans les secteurs des sciences de la vie et de la santé. Avec 1,25 milliard de dollars d’actifs sous gestion, Abingworth est présent à Londres, Menlo Park (Californie) et Boston. Pour en savoir plus, consultez www.abingworth.com

A propos de l’Institut de la Vision
Construit au cœur du Centre Hospitalier des Quinze-Vingts, l’Institut de la Vision (Paris, France) est l’un des plus importants centres de recherche européens sur les maladies de la vision. Conçu comme un lieu de rassemblement et d’échanges, il réunit dans un même lieu les trois acteurs majeurs de la lutte contre les déficiences visuelles – chercheurs, cliniciens et partenaires industriels – dont le but est identique : découvrir, tester et développer des traitements et des technologies innovantes pour prévenir ou limiter les maladies de la vision et améliorer l’autonomie et la qualité de vie des patients. 

Pour en savoir plus, consultez www.institut-vision.org.

 

20/11/2013
  • 50 percent response rate seen in heavily-pretreated FGF
  • aberrant breast cancer patients – Activity observed in other solid tumors with FGFR/VEGFR pathway activation
  • Servier partnership to fund majority of lucitanib R&D expenditures over the next 2-3 years
  • Adds third compound to portfolio with focus on patient selection and companion diagnostics

BOULDER, Colo., November 19, 2013 – Clovis Oncology (NASDAQ:CLVS) announced today that it has acquired EOS (Ethical Oncology Science) S.p.A., a privately-held Italian biopharmaceutical company developing a novel targeted therapy to treat cancer. EOS owns the exclusive global (excluding China) development and commercialization rights for lucitanib, an oral, dual-selective inhibitor of the tyrosine kinase activity of fibroblast growth factor (FGF) receptors 1 and 2 (FGFR1/2) and vascular endothelial growth factor (VEGF) receptors 1-3 (VEGFR1-3). In 2012, EOS sublicensed lucitanib rights in Europe and the rest-of-world (ROW) markets, excluding China, to Les Laboratoires Servier (Servier). Clovis holds exclusive rights for lucitanib in the U.S. and Japan, and will collaborate with Servier on the global clinical development of lucitanib.

In an ongoing Phase I/IIa clinical study, lucitanib has demonstrated multiple objective responses in FGF-aberrant breast cancer patients, and objective responses have also been observed in patients with tumors often sensitive to angiogenesis inhibitors, such as renal cell and thyroid cancer. FGF-aberrations include amplification of the FGFR1 gene as well as amplification of a region of chromosome 11q that contains several FGF ligands, specifically FGF-3, -4 and -19.The initial development program for lucitanib will focus on the approximately 25 percent of women with breast cancer who have FGF-aberrant disease.

FGFs and VEGFs each play a role in tumor growth and angiogenesis and both are validated targets in oncology. Clovis believes lucitanib is unique in its pattern of clinical inhibition of both FGFR and VEGFR tyrosine kinases. As a result, lucitanib has potential to provide benefit to cancer patients by simultaneously targeting two relevant tumor growth pathways in selected patients identified by FGF aberrations. In particular, Clovis believes FGF-aberrant tumors are driven by both FGF and VEGF pathways, and that by inhibiting both, lucitanib can provide more meaningful benefit than single pathway inhibitors.

“We have been interested in lucitanib for some time and are pleased to have acquired EOS to add this program to our portfolio,” said Patrick J. Mahaffy, Clovis Oncology’s president and CEO. “It is highly consistent with our focus on developing targeted therapies that provide meaningful benefit to specific patient populations. We are extremely encouraged with lucitanib’s 50 percent response rate seen to date in heavily pre-treated targeted patients and we intend to develop it aggressively, in collaboration with our partner Servier.” Lucitanib Clinical Development

The first clinical trial of lucitanib was initiated in Europe in July 2010 and is currently ongoing at Institute Gustave-Roussy in Paris with Professor Jean-Charles Soria and at Vall d’Hebron Institute of Oncology in Barcelona with Professor Josep Tabernero. This trial is an open-label, dose-escalation, Phase I/IIa study to determine the maximum tolerated dose (MTD), recommended Phase II dose, efficacy, pharmacokinetics and pharmacodynamics of lucitanib in adult patients with advanced solid tumors.

Doses evaluated in the study ranged from 5mg to 30mg given once per day. Twenty milligrams once per day was identified as the MTD. Overall, the toxicity profile observed to date is consistent with what was expected from preclinical studies and with VEGF inhibitors generally, with hypertension, proteinuria, asthenia and subclinical hypothyroidism being commonly observed. Other common treatment-related adverse events include gastrointestinal symptoms such as diarrhea, abdominal pain, nausea and vomiting.

Subsequent to MTD identification, a dose expansion phase was initiated in defined populations expected to derive benefit from lucitanib, and initial data show encouraging activity in patients who were either FGFaberrant or angiogenesis inhibitor-sensitive. Six of 12 evaluable FGF-aberrant breast cancer patients achieved RECIST partial responses and the median progression-free survival was 9.4 months in these 12 patients. These patients were heavily pre-treated, with at least three or as many as 14 prior treatment regimens. Importantly, two of the responders had previously failed to achieve a response with a selective FGFR inhibitor. Responses were also observed in other tumor types.

A broad Phase II program is being initiated to explore lucitanib in multiple indications including a U.S. study in patients with treatment-refractory FGF-aberrant breast cancer and a global study in patients with metastatic squamous NSCLC. In parallel with these planned Clovis-sponsored studies, a Servier-sponsored Phase II study of lucitanib monotherapy in patients with advanced breast cancer will begin enrolling this month. This ex- US study is expected to enroll approximately 120 patients and will seek to determine whether the activity of lucitanib is limited to a defined population of breast cancer tumors with FGF-aberrations or if a more broadly defined population may benefit as well.

If these Phase II monotherapy studies in breast cancer are successfully completed, Clovis and Servier intend to pursue future development of lucitanib as monotherapy and/or in combination with estrogen antagonists. Other potential indications that may be considered for development include squamous NSCLC, bladder, head and neck cancer, and other solid tumors with FGF-aberrancies.

Clinical development of lucitanib in patients with FGF-aberrant tumors will be accompanied by development of a diagnostic test designed to identify a selected patient population most likely to benefit.

Composition of matter patent protection for lucitanib and a group of structurally related compounds is issued in the United States and is pending in Japan. In the United States, the composition of matter patent will expire in 2030.

Financial Terms
Under the terms of the deal, Clovis is acquiring EOS for an up-front payment of $200 million, which includes $190 million in Clovis common stock (3,713,731 shares) and $10 million in cash. Clovis will pay an additional $65 million in cash upon the initial approval of lucitanib by the U.S. Food and Drug Association (FDA). Pursuant to the license agreement with Servier, Clovis is entitled to receive up to €350 million (approximately $470 million) upon the achievement of development and commercial milestones, as well as royalties on sales of lucitanib in the Servier territories. Clovis will also pay the EOS shareholders up to an additional €115 million in cash (approximately $155 million) upon the receipt by Clovis of certain of the milestone payments pursuant to the Servier license agreement.

Clovis and Servier will collaborate on the development of lucitanib pursuant to a mutually-agreed upon global development plan. Servier is responsible for the initial €80 million (approximately $108 million) of costs under the global development plan and costs above €80 million will be shared equally between the companies.

Clovis intends to host an R&D Day and webcast for institutional investors and analysts to detail its clinical development programs for CO-1686, lucitanib and rucaparib next January in New York City. Slide Presentation and Conference Call Details Clovis will post a lucitanib slide presentation on the Company’s website at www.clovisoncology.com which can be accessed via the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-presentations.Clovis will also hold a conference call to discuss this announcement Wednesday morning, November 20, 2013 at 8:30 a.m. ET. The conference call and slide presentation will be simultaneously webcast on the Company’s web site and archived for future review. Dial-in numbers for the conference call are as follows: US participants 877 703 6110, International participants 857 244 7309, passcode: 12815948.

About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

About Servier 
Servier is a privately-run French research-based pharmaceutical company. Current therapeutic domains for Servier medicines are cardiovascular, metabolic, neurological, psychiatric and bone and joint diseases, as well as oncology. Servier is established in 140 countries worldwide with over 20,000 employees and a 2012 turnover of €3.9 billion. Servier invests 25% of its turnover in R&D. More information is available at: www.servier.com

Contact: Anna Sussman Breanna Burkart 303.625.5022 303.625.5023 asussman@clovisoncology.com bburkart@clovisoncology.com

To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in our clinical development programs, including the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of the drug product candidates because the relate to events, competitive dynamics, and industry change and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Clovis Oncology does not undertake to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Clovis Oncology’s Annual Report on Form 10-K for the year ended December 31, 2012 and its other reports filed with the Securities and Exchange Commission. 

20/11/2013

Avec EOS, Sofinnova finance pour la seconde fois avec succès le même trio d’entrepreneurs italiens

Paris, France. 20 novembre 2013. Sofinnova Partners, société indépendante de capital risque basée à Paris, annonce la vente de Ethical Oncology Science (EOS), une société de son portefeuille basée à Milan (Italie), spécialisée dans le développement de thérapies pour traiter le cancer, à Clovis Oncology pour une valeur d’entreprise totale de 420 M$ (310 M€).

Selon les termes de l’accord, Clovis Oncology (NASDAQ:CLVS) acquiert EOS en échange d’un paiement initial de 200 M$, qui inclut 190 M$ en actions Clovis (3 713 731 actions) et 10 M$ en cash. Un paiement additionnel de 65 M$ interviendra lors de l’approbation par la FDA aux Etats Unis (Food and Drug Administration) du médicament lucitanib que développe EOS. Suite à l’accord de licence avec Les Laboratoires Servier, Clovis pourra bénéficier de 350 M€ (environ 338 M$) sur la base de la realisation d’objectifs commerciaux et de développement, ainsi que de royalties sur les ventes du lucitanib sur les territories couverts par Servier. Clovis paiera également aux actionnaires de Eos des paiements d’étape pouvant aller jusqu’à 115 M€ supplémentaires (environ 155 M$) sur la base de la réalisation d’objectifs liées à l’accord de licence signé avec Servier en 2012.
Investisseur dès la création en 2006, Sofinnova Partners a continué à financer EOS au cours des années suivantes, a fait venir d’autres investisseurs comme Aescap Venture et Principia SGR et est resté l’actionnaire majoritaire jusqu’à aujourd’hui. La société a été créée par Silvano Spinelli, Gabriella Camboni et Ennio Cavaletti, trois entrepreneurs qui ensemble avaient déjà créée Novuspharma, une spin off de Hoffmann La Roche que Sofinnova Partners a également financée dès son démarrage. Novuspharma s’est introduite en bourse en Italie en 2000 puis a été revendue avec succès à CTI, une entreprise de biotechnologie cotée au Nasdaq. EOS développe de nouvelles thérapies ciblées qui répondent à des besoins médicaux non satisfaits pour les patients atteints de cancer. La société détient les droits exclusifs de développement et de commercialisation (sauf Chine) pour le lucitanib, un inhibiteur de kinase ciblant efficacement à la fois les récepteurs Fibroblast Growth Factor Receptor 1 (FGFR1) et Vascular Endothelial Growth Factor Receptor-1-3 (VEGFR-1-3), dont le profil unique lui confère une activité anti-tumorale spécifique dans les tumeurs sur-exprimant le FGFR1. Le lucitanib vise à traiter le cancer du sein ainsi que d’autres tumeurs dite « FGF-aberrant » ou « angiogenesis-sensitive », telles que par exemple le cancer de la thyroïde. Une étude clinique Phase II est actuellement en cours afin d’explorer de nouvelles possibles indications pour le lucitanib. L’acquisition par Clovis s’inscrit à la suite de l’accord avec Servier sur le développement et la commercialisation du lucitanib. Clovis entend collaborer avec Servier sur le développement clinique du lucitanib et maintenir l’exclusivité des droits aux Etats Unis et au Japon.

“Avec EOS, nous avons l’illustration parfaite d’une des stratégies de Sofinnova qui consiste à financer des serial-entrepreneurs sur la durée. Après la vente de Novuspharma, les trois fondateurs étaient désireux de démarrer une nouvelle aventure et nous étions ravis les soutenir à nouveau ”, déclare Antoine Papiernik, Partenaire Associé chez Sofinnova Partners.

“Après le succès de notre première collaboration, il nous a semblé évident de nous tourner vers Sofinnova lorsque nous cherchions les fonds d’amorçage pour EOS. Sofinnova a joué le rôle d’un véritable partenaire, nous accompagnant dans tous les étapes du développement de la société jusqu’à aujourd’hui ”, poursuit Silvano Spinelli, co-fondateur et PDG de EOS.

“Dans le prolongement de l’accord avec Les Laboratoires Servier en 2012, la vente d’EOS à Clovis va nous permettre de poursuivre le développement clinique du lucitanib avec la perspective à terme d’offrir une alternative thérapeutique innovante pour de nombreux patients ”, déclare Dr. Gabriella Camboni, co-fondatrice et Directeur des opérations de EOS.

Contact presse pour Sofinnova Partners
STRATEGIES & IMAGE
Anne Rein
anne.rein@strategiesimage.com
+33 (0)6 03 35 92 05

Contact presse pour EOS
Silvano Spinelli
PDG
silvano.spinelli@eosmilano.com
+39 335 80 78 330

A propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris. Depuis plus de 40 ans, la
société a financé près de 500 sociétés – start-up, spin-off et opérations de retournement. Elle a accompagné
les plus grands entrepreneurs européens dans le domaine des sciences de la vie. Avec 1,3 milliard d’euros sous
gestion, l’équipe de Sofinnova Partners, reconnue pour sa capacité à aider et à soutenir les entreprises de son
portefeuille de la création à la sortie, a permis l’émergence de leaders sur leurs marchés.

A propos de EOS
EOS (Ethical Oncology Science) est une société de biotechnologie basée à Milan en Italie, qui développe des
thérapies ciblées pour les patients atteints de cancer. EOS a été créée par une équipe d’entrepreneurs
expérimentée bénéficiant d’une solide expertise dans le domaine de l’oncologie. Fondée en juin 2006 par
Silvano Spinelli et Gabriella Camboni, la société a financé au démarrage et ultérieurement par ses fondateurs
et le fonds Sofinnova Partners. Pour en savoir plus, consultez www.eosmilano.com/.

A propos de Clovis Oncology
Clovis Oncologyest une société de biopharmacie spécialisée dans le développement de traitements anticancéreux
aux Etats Unis, en Europe et sur les autres marché à l’international. Clovis Oncology est basée à
Boulder, Colorado (USA) et dispose de bureaux à San Francisco, Californie (USA) et à Cambridge (Royaume
Uni). Pour en savoir plus, consultez www.clovisoncology.com

18/11/2013
04/11/2013

Funds to be used to progress viral vaccine pipeline and to explore applications in cancer immunotherapy

VIENNA, AUSTRIA, November 4, 2013 – Hookipa Biotech AG, a company pioneering a new class of vaccines, today announced that it has raised €20 million ($27.5 million) in a series B equity financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing with three new investors, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.

Dr. Katherine Cohen, Chief Executive Officer of Hookipa Biotech said: “We have made very substantial progress in the last two years and are delighted to have the support of a highly experienced syndicate of venture investors. I would like to thank our initial investors for their strong confidence in Hookipa and I look forward to working with our new investors as we enter into the exciting next stage of development.”

Hookipa has developed Vaxwave®, a novel and proprietary viral vector platform with exquisite capacity for the stimulation of antibody and CD8+ T cell immunity. The Company’s lead product candidate based on this platform, HB101, is a vaccine against cytomegalovirus (CMV) that is currently in advanced pre-clinical development and testing. The new investment will be used to progress HB101 into Phase I clinical testing and to further industrialize Vaxwave® technology, both for partnering and for building a robust product pipeline in the area of infectious diseases and cancer.

Hookipa’s Vaxwave® technology exhibits great potential for cancer immunotherapy, since Vaxwave® vectors are not inhibited by anti-vector immunity and can be repeatedly administered for stimulating potent CD8+ T cell responses against tumor targets. The series B financing will thus also be used to explore applications for novel cancer therapies.

Graziano Seghezzi, Partner at Sofinnova Partners, the founding investor of Hookipa Biotech, commented: “Since Sofinnova’s seed investment in early 2011, Hookipa has developed from a scientific concept into an innovative early-stage vaccine company. Dr. Cohen’s decisive leadership has been instrumental in rapidly assembling a team of experienced vaccine specialists that have made great progress with the Vaxwave® technology. The strength and diversification of the investors in this Series B syndicate is testament to the potential of the technology and the abilities of the team. I am looking forward to continuing to work with Dr. Cohen and the board to successfully progress Hookipa through its next phase of growth.”

The Company also welcomes Dr. Frank Kalkbrenner from the Boehringer Ingelheim Venture Fund as a new member of the company’s Supervisory Board and Dr. Yuji Iizawa from Takeda Ventures and Dr. Markus Hosang from BioMedPartners as Observers. “We believe the Vaxwave® technology is a ground-breaking platform with potential not only as a prophylactic and therapeutic vaccine in infectious diseases but also as a potential therapeutic approach in the field of oncology. I am pleased to be joining the board together with two seasoned early stage investors, Forbion and Sofinnova, and look forward to working with the experienced team at Hookipa Biotech” commented Dr. Kalkbrenner.

This financing brings the total equity finance raised by Hookipa to €27.5 million. It announced a series A investment of €7 million in October 2011.                                                                                                                                  

22/10/2013

This Proof of concept study aims to capitalize on DBV’s safe and non-invasive technology and Inserm’s unique expertise to address refractory Hemophilia A, a severe orphan disease with no cost-effective and convenient treatment today available to patients

BAGNEUX, FRANCE, October 22nd, 2013 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a
new standard in the treatment of allergies, announced today that it has entered into a research collaboration with Institut
national de la Santé et de la recherche médicale, Inserm and Inserm Transfert, to investigate the effect of epicutaneous
delivery of recombinant Factor VIII (FVIII) protein via Viaskin in an animal model of hemophilia A. DBV and Inserm are
teaming up to combine the Viaskin® technology and a world-class expertise in hemophilia A to develop a potential standard
of care for refractory hemophilia A patients, by providing a cost-effective, and non-invasive treatment.

Dr. Sébastien Lacroix-Desmazes, CNRS (Inserm Team UMRS 872, Immunopathology and Therapeutic Immuno-
Intervention), said, “Preventing the immune response to therapeutic proteins upon induction of tolerance is the approach of
choice for patients with hemophilia A. To date, the only strategy to induce tolerance to FVIII in patients who have developed
anti-FVIII antibodies consists in flooding the immune system with enormous amounts of FVIII every day, for periods that can
extend up to several months or years. This obviously faces issues with patients’ compliance and treatment costs. Being able
to induce FVIII-specific tolerance in hemophilia A patients using low doses of antigen, such as is the case with the Viaskin
delivery system, would drastically improve the life of alloimmunized hemophilia A patients and solve a crucial societal
burden.”

Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said, “The establishment of a partnership with Dr.
Sebastien Lacroix-Desmazes and Inserm, with their extensive expertise in Hemophilia A, can potentially open a new path for
Viaskin to become the future of hemophilia A treatment as a non-invasive, prophylactic alternative against an alloimmune
response to therapeutic Factor VIII.” Dr. Pierre-Henri Benhamou concluded: “This research should reinforce the relevance of
the Viaskin® platform, as a technology enabling deep and durable modulation of inappropriate immune responses.”

The protective effect conferred by the immunological response induced by epicutaneous immunotherapy using Viaskin®
will be tested at the humoral level, and is expected to induce tolerance to FVIII in mice with severe hemophilia A. The DBVInserm
research collaboration will last 12 months. Different mice cohorts will be treated with Viaskin containing the FVIII
protein versus placebo for 45 days. After 45 days, all mice will be subject to a protocol of replacement therapy for 4 weeks.
The levels of anti-FVIII IgG and of FVIII inhibitors will then be assessed by immunological and functional assays. Various
approaches have investigated treatments aimed at inducing tolerance to exogenous FVIII in hemophilic mice. Through the
Viaskin platform, DBV Technologies has developed a first-in-class approach to deliver antigens of choice to immunosensitized
organisms as a method to induce antigen-specific tolerance, and in this case, tolerance to therapeutic FVIII in
hemophilia A.

About Hemophilia A
Hemophilia A is a rare X chromosome-linked recessive hemorrhagic disorder that affects one individual out of 5,000—
10,000. Genetic abnormalities in the gene encoding FVIII result in the absence of production of FVIII or in the production of
defective FVIII molecules. In up to 30% of the patients, replacement therapy is complicated by the occurrence of anti-drug
antibodies, referred to as inhibitory anti-FVIII antibodies (or FVIII inhibitors), that preclude the use of FVIII as treatment.
Inhibitory anti-FVIII antibodies are of the IgG isotypes, and mostly part of the IgG1 and IgG4 subclasses. Mortality is high
and ranging between 12.5% and 22%, usually because of fatal hemorrhage.

About Inserm
Understand and improve human health
Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute
which operates under the joint authority of the French Ministry of Health and French Ministry of Research.
As the only French public research institute to focus entirely on human health, in 2008 Inserm took on the responsibility for the
strategic, scientific and operational coordination of biomedical research. This key role as coordinator comes naturally to Inserm thanks to
the scientific quality of its teams and its ability to conduct translational research, from the laboratory to the patient’s bed.
In April 2009, national coordination was strengthened by Aviesan, the Alliance nationale pour les sciences de la vie et de la santé (French
National Alliance for Life and Health Sciences), which Inserm co-founded with other research institutes and the Conférence des
présidents d’université (Association of University Presidents).

About DBV Technologies
DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly
increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major
unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an
allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a
treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in
the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method
through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective
desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies
is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products:
Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the
US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite
allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares
are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

CAUTION: Viaskin® is not approved for sale in the USA.

Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Company’s management strategy, current
views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance
or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages
each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with
regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained
during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the product concerned. DBV technologies’ business is subject to the risk factors outlined in
its registration documents filed with the French Autorité des Marchés Financiers.

DBV Contacts
DBV Technologies
David Schilansky
Chief Financial Officer
Tél. : +33(0)1 55 42 78 75
david.schilansky@dbv-technologies.com

US & UK investors
The Trout Group
Investor Relations
Alan S. Roemer
Tél. : +1 (646) 378-2945
aroemer@troutgroup.com

French investors
NewCap.
Financial Communication and investor relations
Emmanuel Huynh / Valentine Brouchot
Tél. : +33(0)1 44 71 94 94
dbv@newcap.fr
US press & media
Ronald Trahan Associates Inc.
Press relations
Ronald Trahan, APR
Tél. : +1 508 359 4005
rctrahan@ronaldtrahan.com
Inserm Contacts
presse@inserm.fr
Tel. : +33(0)1 44 23 60 97

21/10/2013
  • Stallergenes pourra exercer une option de développement et de commercialisation sur un nouveau produit dans l’allergie au pollen de bouleau 
  • DBV est éligible à des paiements d’étape ainsi que des redevances sur les ventes de Stallergenes  
  • Stallergenes acquiert une participation dans DBV 

 

ANTONY et BAGNEUX, France, le 18 octobre 2013 – Stallergenes S.A. (Euronext Paris : GENP), leader mondial de l’immunothérapie allergénique, et DBV Technologies (Euronext Paris : DBV), créateur du Viaskin®, une nouvelle référence dans le traitement de l’allergie, ont annoncé avoir signé un accord de recherche et de développement pour la mise au point d’un nouveau traitement de l’allergie au pollen de bouleau. Cette collaboration est le premier accord s’inscrivant dans le cadre du partenariat entre les deux sociétés dédié au développement de traitements innovants dans le domaine des allergies respiratoires. L’accord signé aujourd’hui permettra d’associer l’expertise mondialement reconnue de Stallergenes dans le domaine des allergies respiratoires à la nouvelle technologie de délivrance épicutanée de DBV, Viaskin®, permettant de moduler la réponse immunitaire.

 

Pour télécharger la version française du communiqué de presse, cliquez sur le lien:
Stallergenes et DBV Technologies signent une collaboration de recherche

14/10/2013

List Recognizes the Top Private Companies in Clean Technology
Amsterdam, the Netherlands – October 10, 2013 Today Cleantech Group, a global market intelligence and consulting firm announced that Avantium, is named in the prestigious 2013 Global Cleantech 100. This is the fourth year in a row that Avantium is named in this unique list, in which the promise of private clean technology companies from all around the world is highlighted. The Cleantech Group focuses on those companies which the players in the market feel are currently the most likely to make the most significant market impact over the next 5-10 years.
―This is our fourth consecutive year to be named in the Global Cleantech Top 100. We are very pleased that the jury confirms our potential to change the world with our YXY technology to produce PEF. It is our goal to make PEF the next generation plastic. Avantium was listed in the Global Cleantech 100 in 2010 for the first time, and our progress has accelerated since that period. We established partnerships with The Coca-Cola Company, Danone, and ALPLA. These industry leaders joined Avantium in developing and commercializing PEF bottles for major consumer markets. We have successfully scaled our YXY technology from lab to pilot plant scale. Our 100% biobased PEF bottles perform superiorly compared to today’s bottles at competitive costs. Being listed in the Global Cleantech 100 is a great recognition of our progress at an important time in the development of our company‖ said Tom van Aken, CEO of Avantium.
The list is derived from Cleantech Group’s own data and research, combined with the weighted qualitative judgments of hundreds of nominations, and the viewpoints of a global 90-person expert panel. This panel was drawn principally from leading financial investors and representatives of multi-national corporations, located in Asia, Europe, and North America. This diversity results in a list of companies that command a broad base of respect and support from many important players within the global cleantech innovation ecosystem. To qualify for the list, companies must be independent, for-profit, cleantech companies that are not listed on any major stock exchange.
―The Global Cleantech 100 is a natural extension of our vision to help corporations and investors connect with innovation around the world,‖ said Sheeraz Haji, CEO of Cleantech Group. ―This list celebrates inspiring entrepreneurs, and serves as the industry standard on gauging where innovation is headed across key sectors.‖
This year 5,864 companies from 60 countries were nominated. These companies were weighted and scored to create a short list of 300 companies. Vital information on these short-listed companies—including key data from Cleantech Group’s i3 platform—was presented to the expert panel for final input. The end result was 100 companies from 18 countries.

About Cleantech Group
Cleantech Group helps clients accelerate sustainable innovation. The company’s i3 platform allows subscribers to discover companies and explore cleantech trends strategically with proprietary real-time data. Cleantech Forums bring together thought leaders and innovators in the cleantech and sustainability ecosystem. The company’s advisory services leverage expertise in designing and
executing corporate strategies for sustainable growth and innovation sourcing. Details at www.cleantech.com
For more information about Cleantech Group, please contact Millen Paschich: tel: +1 (415) 233 9712, email: media-services@cleantech.com.

About Avantium
Avantium is a leading technology company specialized in the area of advanced high-throughput R&D. The company develops and commercializes YXY – the brand name for its technology platform to catalytically convert plant based carbohydrates into chemical building blocks like Furanics and Levulinics. These chemical building blocks can be applied for making green materials with superior product properties at competitive pricing. Currently the focus of the YXY technology platform is on a building block called FDCA, (2,5- furandicarboxylic acid). FDCA can be polymerized together with ethylene glycol (EG) to form PEF (Polyethelyne Furanoate), which is Avantium’s lead application. Combined with the significant reduction in carbon footprint, PEF fulfills key criteria to become the next generation biobased plastics for bottles, film and fibers. PEF for example has gas barrier to oxygen, carbon dioxide and water is superior to PET, leading to longer product shelf life and offering the potential for light weighting of packages. Avantium has demonstrated the value and commercial potential of its unique technology by collaborating with leading companies in the energy and chemical industries. Avantium offices and headquarters are based in Amsterdam, the Netherlands, and Avantium is running an YXY pilot plant in Geleen, the Netherlands.
For more information about Avantium, please contact Mariette Hoogendoorn: tel: +31 (0)20 5868010, email: info@avantium.com.

01/10/2013

Minneapolis, Oct. 1, 2013 – BioAmber Inc. (NYSE: BIOA) announced today a payment to Cargill for achieving the final milestone in their development agreement, under which BioAmber has exclusively licensed the Cargill yeast technology for succinic acid production. Completion of this milestone signals that the succinic acid producing yeast has met performance expectations. BioAmber began work in August 2013 on a 30,000 MT plant in Sarnia, Ontario, and has engineered the facility to operate with this proprietary yeast.
« This milestone achievement is the culmination of three years of joint development with Cargill. We licensed this yeast in 2010 because we strongly believed it is the best technology platform in the industry for making organic acids, and because Cargill has experience in the development and commercialization of organic acids that strengthened our succinic acid program, » said Jim Millis, BioAmber’s Chief Technology Officer.
« BioAmber and Cargill’s collaboration has been successful and our yeast technology has proven effective for making succinic acid. We look forward to BioAmber commercializing the yeast when it brings on line its bio-succinic acid facility in Sarnia, » said Gary Folkert, Cargill’s Biotechnology Director of Licensing.
« Our proprietary technology platform has been significantly strengthened with the Cargill yeast. This is an important milestone and we plan to continue to work with Cargill to develop alternative feedstock options for our succinic acid platform and to bring to market our adipic acid yeast platform, which we have also licensed exclusively from Cargill, » said Jean-Francois Huc, BioAmber’s Chief Executive Officer.

About BioAmber
BioAmber (NYSE and EURONEXT Paris: BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products. For more information, visit www.bio-amber.com.

About Cargill
Cargill is an international producer and marketer of food, agricultural, financial and industrial products and services. Founded in 1865, the privately held company employs 140,000 people in 65 countries. Cargill helps customers succeed through collaboration and innovation, and is committed to applying its global knowledge and experience to help meet economic, environmental and social challenges wherever it does business. For more information, visit www.cargill.com.

30/09/2013

La Motte-Fanjas, France, Sept. 27, 2013 / – Inauguration of large-scale, onsite system for both generating hydrogen by electrolysis of water and storing it in a safe, solid form
McPhy Energy, a leading developer and manufacturer of solid state hydrogen storage, presented today the world’s first system coupling an industrial-scale hydrogen generator with a 100 kg solid hydrogen storage unit. The demonstration, which showed the results of the first phase of the French PUSHY program, was given at the company’s headquarters in La Motte-Fanjas, in the department of the Drome,France. While such systems enable the supply of onsite hydrogen for industry, they also mark a world premiere in the transition to renewable energies, enabling approaches such as « power-to-gas » and hydrogen mobility to become both technical and commercial realities.

The McPhy Energy technology for storing hydrogen in the form of hydrides is a safe, low-pressure, high-density solution.
The generator, which produces hydrogen through the electrolysis of water, is manufactured by McPhy Italy and powered by 60 KW of electricity from the local electrical grid. The demonstrator shown today can produce 12m[3]of hydrogen per hour. The gas is then stored in McPhy’s HDS 100 system, which is based on magnesium hydride technology developed and manufactured by McPhy Energy in La Motte-Fanjas, France.
The system inaugurates the first commercial product line for onsite industrial hydrogen users worldwide. This first model, which has a storage capacity of 100 kg (for an energy content of 3.3 MWh), is the first in a commercial range reaching up to 500 kg of stored hydrogen (16.5 MWh).
It enables traditional hydrogen logistics (high-pressure delivery) to be replaced with production that is located at the point of use and aligned with demand. This ambitious project, funded by BPI France (formerly OSEO/ISI) was developed in an industrial consortium lead by McPhy Energy, with the CEA (the French Atomic & Alternative Energy Agency) and the company WH2.
« The pilot presented today at our manufacturing site in La Motte-Fanjas is the first deliverable of the PUSHY project. In 2014, it will be followed by a demonstration of hydrogen production by hydroelectric energy, for the storage and exploitation of renewable energies inFrance as in Europe and across the globe, » said Pascal Mauberger, CEO of McPhy Energy. « With the deployment of renewable energies, storage requirements are substantial, and solutions are needed to respond to those needs. That is the objective of this demonstrator model, which marks the beginning of a complete line of groundbreaking products. »

About McPhy Energy
McPhy Energy S.A., which is headquartered near Grenoble, France, develops and manufactures innovative and safe hydrogen technologies. Besides solid-state storage of hydrogen based on metal hydrides, McPhy is consistently expanding activities in on-site generation of hydrogen by means of water electrolysis. With the acquisition of PIEL (Italy) in early 2013, McPhy now has a global installed base of over 3000 systems. For three consecutive years, McPhy has been listed in the « Global CleanTech 100 » group of companies and is one of the « Top 5 CleanTech France » enterprises. The Group has manufacturing sites in France and Italy.